Avadel Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Avadel Pharmaceuticals has a total shareholder equity of $78.4M and total debt of $34.3M, which brings its debt-to-equity ratio to 43.8%. Its total assets and total liabilities are $167.9M and $89.5M respectively.
Key information
43.8%
Debt to equity ratio
US$34.33m
Debt
Interest coverage ratio | n/a |
Cash | US$88.79m |
Equity | US$78.38m |
Total liabilities | US$89.52m |
Total assets | US$167.90m |
Recent financial health updates
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Jan 16Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Sep 22Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt
Jul 07Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Mar 15Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Nov 19Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jul 23Recent updates
Avadel Pharmaceuticals: Inflection Point Ahead
Jun 16Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Apr 02Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Mar 05Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Jan 28Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Jan 16Avadel May Continue To Outperform With Positive Launch Momentum
Jan 11Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Sep 22Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?
Aug 01Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?
May 03Avadel Pharmaceuticals filed for 500M mixed shelf offering
Aug 31Avadel Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt
Jul 07Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023
Jun 29Avadel: Further Delay, But Some Light At The End Of The Tunnel
Jun 16Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness
Mar 21Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Mar 15Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Nov 19Avadel Pharmaceuticals: I Am Holding
Nov 01Avadel Pharmaceuticals, The Jazz-Killer
Aug 05Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jul 23Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy
Jun 09Avadel Pharmaceuticals EPS beats by $0.09
May 10Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021
Mar 11Is Avadel Pharmaceuticals plc (NASDAQ:AVDL) Popular Amongst Institutions?
Feb 05Avadel Pharmaceuticals' (NASDAQ:AVDL) Stock Price Has Reduced 35% In The Past Three Years
Jan 10Avadel files US application for its lead drug
Dec 16Avadel's Xyrem Competitor: A Quick Overview
Dec 15Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Dec 15Financial Position Analysis
Short Term Liabilities: AVDL's short term assets ($136.0M) exceed its short term liabilities ($47.8M).
Long Term Liabilities: AVDL's short term assets ($136.0M) exceed its long term liabilities ($41.7M).
Debt to Equity History and Analysis
Debt Level: AVDL has more cash than its total debt.
Reducing Debt: AVDL had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVDL has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: Insufficient data to determine if AVDL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.